NCT06216392View on ClinicalTrials.gov

Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

January 31, 2026

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

GR1802 injection

150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

BIOLOGICAL

placebo

0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Trial Locations (1)

200000

Huashan Hospital, Shanghai

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY